Back to top
more

Novavax (NVAX)

(Real Time Quote from BATS)

$14.22 USD

14.22
1,948,921

+0.37 (2.67%)

Updated Jul 22, 2024 11:34 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (71 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Novavax (NVAX) Down on COVID Jab-Manufacturing Problem Reports

by Zacks Equity Research

Novavax's (NVAX) shares fall on reports of the company's manufacturing problems related to its COVID-19 vaccine candidate.

Novavax (NVAX) Lags in COVID Vaccine Race: Will It Gather Pace?

by Zacks Equity Research

Novavax (NVAX) is progressing well with its COVID-19 and flu vaccines. However, it is lagging in the COVID-19 vaccine space. Let us see how the company is likely to perform going forward.

Novavax (NVAX) Concentrates on COVID-19 Vaccine Development

by Zacks Equity Research

While Novavax's (NVAX) COVID-19 vaccine shows potential, delay in regulatory filings in both the United States and Europe does not bode well for the stock.

Is iShares MSCI USA Equal Weighted ETF (EUSA) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for EUSA

3 Drugmakers in Focus After Merck's Positive COVID-19 Pill Data

by Zacks Equity Research

Here we discuss three other pharma or biotech companies with promising oral drug candidates for treating COVID-19 following Merck's (MRK) announcement of promising clinical data on its oral therapy.

Kinjel Shah headshot

Vaccine Stocks Down Following Merck's COVID-19 Pill Success

by Kinjel Shah

Stocks of several COVID-19 vaccine makers declined on Friday after Merck (MRK) released positive data for a new oral antiviral treatment for COVID-19

J&J (JNJ) Starts Phase III Study on RSV Vaccine in Older Adults

by Zacks Equity Research

J&J (JNJ) starts the phase III study on its RSV vaccine candidate in adults aged 60 years and above.

Novavax (NVAX) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Novavax (NVAX) closed the most recent trading day at $203.53, moving -0.63% from the previous trading session.

Biotech Stock Roundup: XLRN Up on Takeover Rumor, NVAX, BIIB Offer Updates & More

by Zacks Equity Research

Regulatory and pipeline updates from bigwigs like Biogen (BIIB) and Novavax (NVAX) have been some of the key highlights in the biotech sector during the past week.

Novavax (NVAX) Applies to WHO for COVID-19 Vaccine Listing

by Zacks Equity Research

On being granted the emergency use listing for Novavax's (NVAX) COVID-19 vaccine by WHO, it is to become eligible to supply the same to numerous countries participating through the COVAX facility

Novavax (NVAX) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Novavax (NVAX) closed at $230.29 in the latest trading session, marking a +1.49% move from the prior day.

Pfizer, Moderna Support COVID Vaccine Booster Before FDA Meet

by Zacks Equity Research

Amid rising coronavirus cases, PFE and MRNA are trying to make booster doses of their COVID-19 vaccine available for US citizens. An FDA meeting is scheduled tomorrow to discuss Comirnaty's booster dose.

Novavax (NVAX) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Novavax (NVAX) closed at $234.29 in the latest trading session, marking a +0.2% move from the prior day.

Is iShares MSCI USA Equal Weighted ETF (EUSA) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for EUSA

Novavax (NVAX) Stock Surges YTD as COVID Vaccine Advances Well

by Zacks Equity Research

Upon approval and successful commercialization, Novavax's (NVAX) COVID-19 vaccine should reap huge revenues. The company's other pipeline candidates also show promise.

Novavax (NVAX) Begins Clinical Study on COVID/Flu Combo Jab

by Zacks Equity Research

Novavax (NVAX) starts enrolling patients in a phase I/II study to evaluate a combination of its COVID vaccine and seasonal influenza vaccine.

Pfizer (PFE) Begins Study on RSV Vaccine in Older Adults

by Zacks Equity Research

Pfizer (PFE) starts a phase III study which will evaluate its respiratory syncytial virus vaccine candidate, RSVpreF in adults aged 60 years and above.

3 Large Biotech Stocks Worth Adding to Your Portfolio

by Zacks Equity Research

REGN, MRNA & VRTX are the three biotech companies that are likely to outperform the sector on the back of strong fundamentals.

The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Moderna, Johnson & Johnson and Novavax

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Moderna, Johnson & Johnson and Novavax

3 COVID Vaccine Makers to Watch on Pfizer Jab Full FDA Approval

by Zacks Equity Research

Stocks of coronavirus vaccine makers BNTX and MRNA fly high following complete approval of Pfizer's COVID-19 vaccine. The momentum is likely to continue for these stocks. JNJ is another strong contender in this field.

Is iShares MSCI USA Equal Weighted ETF (EUSA) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for EUSA

Madeleine Johnson headshot

Why Novavax (NVAX) Stock Fell 19% on Friday

by Madeleine Johnson

Shares of the biotech firm plunged 19.6% in Friday trading after it delayed U.S. submission for its Covid-19 vaccine for the third time.

Novavax's (NVAX) Q2 Loss Widens, Revenues Miss, Shares Down

by Zacks Equity Research

Novavax (NVAX) reports wider-than-expected loss in the second quarter of 2021 while revenues also miss estimates. Shares down in after-hours trading.

Novavax (NVAX) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Novavax (NVAX) delivered earnings and revenue surprises of -26.33% and -19.63%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Novavax (NVAX) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

On Novavax's (NVAX) upcoming second-quarter earnings call, investor focus is likely to be on the company's progress with its COVID-19 vaccine candidate, NVX-CoV2373.